

# QuiremSpheres® treatment of a 47-year-old female patient with mCRC after multiple hepatic resections

Physician: Giuseppe Boni, MD; Irene Bargellini, MD; Elena Bozzi, MD; Rosa Cervelli, MD; Claudio Antonio Traino; Duccio Volterrani, MD; Roberto Cioni, MD

Location: Pisa University Hospital; Italy

## CLINICAL CASE

A 47-years old female patient diagnosed with left colon adenoCa (KRAS mut codon 13, BRAF wt, NRAS wt, MSS) and synchronous hepatic metastasis three years before, treated with multiple hepatic resections, percutaneous ablation and >3 lines of systemic chemotherapy. Patient presents with mild hepatic progression and stable subcentimetric bilateral lung metastases (ECOG 0, normal liver function).


## PROCEDURE

SIRT was approved by multidisciplinary tumor board. Based on vascular anatomy angiography, <sup>99m</sup>Tc-MAA were injected in the hepatic artery nourishing the entire residual liver parenchyma. Lung shunt was 9.6%. The total tumor volume was 27cc. A reduced dose of 40 Gy (instead of 60 Gy) was planned on the remnant liver volume (1093 cc) because of prior partial resection and chemotherapy.


QuiremSpheres® (<sup>166</sup>Ho-PLLA microspheres) with a total net activity of 2.2 GBq were injected via a 2.7F microcatheter. Treatment was well-tolerated with no periprocedural complications.

## FOLLOW UP/ CONCLUSION


Post-treatment SPECT-CT and T<sub>2</sub>\* MRI showed excellent concentration of the microspheres in the liver lesions. Forty-five days after SIRT, CT demonstrated reduction in size of the majority of the hepatic lesions, the largest showing peripheral calcifications. Accordingly, PET-CT showed only a faint <sup>18</sup>F FDG uptake of the hepatic metastasis. However, extrahepatic tumor progression was observed consisting in increased lung metastases and abdominal lymph nodes.



Baseline CT



Dose distribution based on T<sub>2</sub>\*-weighted MRI calculated with Q-Suite™.



6 weeks follow-up CT

QuiremSpheres® is a product manufactured by Quirem Medical B.V. and has CE-mark. QuiremSpheres® is not available for sale in all countries. This information is provided only in respect to markets where the product is approved or cleared. QuiremSpheres® is not FDA cleared in the US for sale. QuiremSpheres® is not approved in Canada. Terumo is the exclusive distributor for QuiremSpheres®

<https://www.terumo-europe.com/en-emea/Treat-liver-cancer-with-Terumo-2018>

byagency

PUSHING BOUNDARIES

**TERUMO**  
INTERVENTIONAL  
SYSTEMS